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Machado-Joseph disease (MJD) is a neurodegenerative disorder associated with an 
abnormal CAG expansion, which translates into an expanded polyglutamine tract within 
ataxin-3. There is no therapy to prevent or modify disease progression. Since caffeine (a 
non-selective adenosine receptor antagonist) and selective adenosine A2A receptor (A2AR) 
blockade alleviate neurodegeneration in different brain diseases, namely at early stages of 
another polyglutamine-related disorders such as Huntington’s disease, we now tested their 
ability to control MJD-associated neurodegeneration. 
Methods: 
MJD was modelled by transducing the striatum of male adult C57Bl6 mice with lentiviral 
vectors encoding mutant ataxin-3 in one hemisphere and wild-type ataxin-3 in the other 
hemisphere (as internal control). Caffeine (1 g/L) was applied through the drinking water. 
Mice were killed at different time points (from 2-12 weeks) to probe for the appearance of 
different morphological changes using immunohistochemical analysis.  
Results: 
Mutant ataxin-3 caused an evolving neuronal dysfunction (loss of DARPP-32 staining) 
leading to neurodegeneration (Cresyl violet and NeuN staining) associated with increased 
number of mutant ataxin-3 inclusions in the basal ganglia. Notably, mutant ataxin-3 triggered 
early synaptotoxicity (decreased synaptophysin and MAP-2 staining) and reactive gliosis 
(GFAP and CD11b staining), which predated neuronal dysfunction and damage. Caffeine 
reduced the appearance of all these morphological modifications, which were also abrogated 
in mice with a global A2AR inactivation (knockout).  
Interpretation: 
Our findings provide a demonstration that synaptotoxicity and gliosis are precocious events 
in MJD and that caffeine and A2AR inactivation decrease MJD-associated striatal pathology, 
which paves the way to consider A2AR as novel therapeutic targets to manage MJD. 
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Various inherited neurodegenerative diseases result from an increase in the number of 
CAG codon repeats within the open reading frame of the responsible gene.1 Machado-
Joseph disease (MJD) or spinocerebellar ataxia type 3, is one such dominantly-inherited 
polyglutamine neurodegenerative disease and the most common among ataxias.2 It is 
characterised by an adult age of onset causing premature death associated with unstable 
expansion of a CAG stretch (over 55 repeats) in the MJD1 gene that encodes a 
polyglutamine repeat in the corresponding ataxin-3 protein.3,4 The clinical hallmarks of MJD 
include progressive ataxia, dysfunction of motor coordination, postural instability and 
Parkinsonism among other symptoms.5,6 The neuropathology of MJD involves multiple 
systems such as cerebellar systems, substantia nigra and cranial nerve motor nuclei,3,7 as 
well as the striatum.8-11 Degeneration and loss of neuronal cells in MJD is accompanied by 
the presence of protein aggregates,12 designated as neuronal intranuclear inclusion bodies 
(NIIs). Although transgenic animal models closely mimicking the human pathology,8,13-15 have 
bolstered our understanding of MJD, the mechanisms accounting for neuronal degeneration 
are still largely unknown. Albeit not yet explored in MJD, studies in other polyQ disorders 
suggest that neuronal dysfunction and synaptotoxicity may precede degeneration and 
appearance of clinical symptoms,16,17 and that neuroinflammation,18 may function as an 
amplificatory loop exacerbating neuronal damage.19-21 
There is currently no therapy to manage MJD. We posed that chronic caffeine 
consumption, which affords neuroprotection through the antagonism of adenosine A2A 
receptors (A2AR),
22 might be a candidate strategy to manage MJD neurodegeneration. 
Caffeine and A2AR blockade afford robust neuroprotection in different neurodegenerative 
disorders, in accordance with the key role of A2ARs controlling synaptic viability, apoptotic 
neuronal death, astrocytic function and neuroinflammation.23,24 In particular, in Huntington’s 
disease, another polyQ disorder, A2AR blockade at the prodrome or early stages of the 
disease seems to delay the appearance of clinical symptoms, mainly through a normalization 
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of striatal glutamatergic transmission, which impedes the characteristic degeneration of 
striatal neurons.25 Importantly, it has recently been shown in induced pluripotent stem cells-
derived neurons that glutamate overstimulation raises intracellular calcium levels activating 
the cysteine proteases calpains and promoting the proteolysis and aggregation of ataxin-3.26 
Moreover, calpain-mediated proteolysis of ataxin-3 in a rodent model of MJD mediates 
translocation of ataxin-3 to the cell nucleus, aggregation and neurodegeneration, which can 
be prevented by calpain inhibition.27  
In view of this proposed key role of glutamate overstimulation in MJD, we now 
investigated the time course of neuropathological modifications in a genetic model of MJD 
and tested the novel hypothesis that the manipulation of A2AR function might also be 
beneficial in MJD. 
Materials and Methods 
Animals 
Male C57BL/6 mice (Charles River, Barcelona, Spain) were housed and kept under a 
conventional 12-h light-dark cycle maintained on a temperature-controlled room with food 
and water provided ad libitum and used at 7 weeks of age. C57Bl/6-background A2AR 
knockout (A2AR KO) and age-matched wild type control mice were obtained from parallel 
breeding of our colony of A2AR KO mice, initially obtained from J.F.Chen (Boston 
University).28 The experiments were carried out in accordance with the European Community 
directive (86/609/EEC) for the care and use of laboratory animals. 
Drug treatment 
We chose the dose of caffeine (1 g/L) administered through the drinking water, as a 
maximally effective and non-toxic dose, which we have previously shown to result in a 
plasma concentration of 50 µM,29 and similar concentration in the brain parenchyma,30 
corresponding to a diary human consumption of circa 5 cups of coffee. Treatment with 
caffeine was begun 3 weeks before viral delivery onwards, since we have previously 
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reported that a minimum period of 2 weeks is required to allow a metabolic stabilization after 
beginning the free access to caffeine drinking.29, 31 
Viral vectors production 
Lentiviral vectors encoding human wild-type ataxin-3 (atx3-27Q) or mutant ataxin-3 
(atx3-72Q),8 were produced in 293T cells with a four-plasmid system, as previously 
described.32 The lentiviral particles were resuspended in 1% bovine serum albumin in 
phosphate-buffered saline (PBS). The viral particle content of batches was determined by 
assessing HIV-1 p24 antigen levels (RETROtek, Gentaur, Paris, France). Viral stocks were 
stored at -80ºC until use. 
In vivo injection into the striatum 
Concentrated viral stocks were thawed on ice. After anesthesia of the mice with avertin 
(12 µL/g, i.p.), lentiviral vectors encoding human wild-type (atx3-27Q) or mutant ataxin-3 
(atx3-72Q) were stereotaxically injected into the striatum in the following coordinates: antero-
posterior: +0,6mm; lateral: ±1,8mm; ventral: -3,3mm; tooth bar: 0, which corresponds to the 
internal capsule, a large fiber tract passing through the middle of the striatum dividing both 
dorso-ventral and medial-lateral structures. Wild-type and A2AR KO mice received 2 µL 
injections of lentivirus (200’000 ng of p24/mL) in each hemisphere, administering mutated 
ataxin-3 (atx3-72Q) in the right hemisphere and control wild type ataxin-3 (atx3-27Q) in the 
left hemisphere. Different groups of mice were kept in their home cages for different periods 
ranging from 2, 4, 8 and 12 weeks, before being killed for immunohistochemical analysis of 
morphological and neurochemical changes in the striatum. 
Immunohistochemical procedure 
After an overdose of avertin (2.5x 12 µL/g, i.p.), transcardiac perfusion of the mice was 
performed with PBS followed by fixation with 4% paraformaldehyde. The brains were then 
removed and post-fixed in 4% paraformaldehyde for 24h and cryoprotected by incubation in 
25% sucrose/ phosphate buffer for 48h. The brains were frozen and 25 µm coronal sections 
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were cut using a cryostat (LEICA CM3050 S, Heidelberg, Germany) at -21°C. Slices 
throughout the entire striatum were collected in anatomical series and stored in 48-well trays 
as free-floating sections in PBS supplemented with 0.05 µM sodium azide. The trays were 
stored at 4°C until immunohistochemical processing. 
Sections were processed overnight at 4ºC with the following primary antibodies: a 
mouse monoclonal anti-ataxin-3 antibody (1H9; 1:5000; Chemicon, Temecula, CA), a rabbit 
anti-DARPP-32 antibody (1:1000; Chemicon), or a mouse anti-NeuN antibody (1:1000; 
Chemicon) followed by 2h incubation at room temperature (RT) with the respective 
biotinylated secondary antibodies (1:200; Vector Laboratories, Burlingame, CA). Bound 
antibodies were visualized using the Vectastain ABC kit, with 3,3’-diaminobenzidine 
tetrahydrochloride (DAB metal concentrate; Pierce, Burlingame, CA) as substrate.  
Triple staining for synaptophysin (rabbit polyclonal, 1:300; Chemicon) and MAP2 
(mouse monoclonal AP20, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA), GFAP (rabbit 
polyclonal, 1:1000; DAKO, Glostrup, Denmark) and CD11b (rat monoclonal 5C6, 1:500; AbD 
Serotec, Oxford, UK) together with DAPI (Sigma, St. Louis, MO) were performed. Free-
floating sections were kept at RT for 2h in PBS with 0.1% Triton X-100 containing 10% 
normal goat serum (Gibco-Invitrogen, Barcelona, Spain), then overnight at 4°C in blocking 
solution with the primary antibodies. Sections were washed three times and incubated for 2h 
at RT with the corresponding secondary antibodies coupled to fluorophores goat anti-mouse 
or goat anti-rabbit or goat anti-rat Alexa Fluor 488 or Alexa Fluor 594 (1:200; Molecular 
Probes – Invitrogen, Eugene, OR) diluted in the blocking solution. The sections were washed 
three times and then mounted in mowiol Reagent (Sigma) on microscope slides. 
Definition and analysis of protein immunoreactivities were made from the striatal center 
(site of injection) to the medial-lateral and dorsal-ventral striatal periphery from the needle 
tract. This disease model is based on the intra-striatal injection of lentivirus, which triggers 
physiological alterations evolving over time radially. Therefore, comparable striatal sections 
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between animals were defined from the site of injection in both rostral and caudal directions, 
using the needle tract due to the surgical procedure as reference-point. 
Staining was visualized using Zeiss Axioskop 2 plus, Zeiss Axiovert 200 or Zeiss LSM 
510 Meta imaging microscopes (Carl Zeiss Microimaging, Germany) equipped with AxioCam 
HR color digital cameras (Carl Zeiss Microimaging) and 5X, 20X, 40X and 63X Plan-Neofluar 
or a 63X Plan/Apochromat objectives and using the AxioVision 4.7 software package (Carl 
Zeiss Microimaging). Quantitative analysis of fluorescence was performed with a semi-
automated image-analysis software package (Image J software, NIH, USA). 
Cresyl violet staining 
Coronal sections were pre-mounted and stained with cresyl violet for 45 sec, 
differentiated in 70% ethanol, dehydrated by passing twice through 95% ethanol, 100% 
ethanol and xylene solutions, and mounted onto microscope slides with Eukitt® (Sigma). 
Evaluation of the volume of the DARPP-32 depleted volume and optic density 
The extent of ataxin-3 lesions in the striatum was analyzed by photographing, with a 
x1.25 objective, 8 sections stained with DARPP-32 per animal (25 µm thick sections at 200 
µm intervals), selected so as to obtain complete rostro-caudal sampling of the striatum, and 
by quantifying the area of the lesion with a semi-automated image-analysis software package 
(Image J software). The volume was then estimated with the following formula: volume = 
d(a1+a2+a3 …), where d is the distance between serial sections (200 µm) and a1+a2+a3 are 
DARPP-32-depleted areas for individual serial sections. The average grey value of all pixels 
measured in the lesioned area was recorded for each depleted area. Results are expressed 
as index of immunoreactivity of DARPP-32 considering unlesioned striatal area as 100% 
immunoreactivity. 
Cell counts of ataxin-3 inclusions 
Coronal sections showing complete rostro-caudal sampling (1 of 8 sections) of the 
striatum were scanned with a x20 objective. The analyzed areas of the striatum 
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encompassed the entire region containing ataxin-3 inclusions, as revealed by staining with 
the anti-ataxin-3 antibody. All inclusions were manually counted using a semi-automated 
image-analysis software package (Image J software). 
Statistical analysis 
Statistical comparisons were performed using either an unpaired Student’s t test or 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison post hoc 
test. Results are expressed as mean ± standard error of the mean (SEM). Significance 
thresholds were set at p < 0.05, p < 0.01 or p < 0.001, as defined in the text. 
Results 
Time course 
We took advantage of using a lentiviral model of MJD to perform a temporal analysis of 
the relative appearance of different features from early dysfunction to late neuronal loss. 
Thus, we carried out a time-course study from 2 to 12 weeks upon lentiviral-mediated 
expression of wild-type and mutant ataxin-3, and we analysed different neuropathological 
features such as markers of synaptic loss, neuronal dysfunction, neuronal loss, of 
astrogliosis and microgliosis as well as ataxin-3 inclusions. Figure 1 summarises the 
temporal evolution of each of these changes, which will be further detailed below. 
Neuronal degeneration and loss 
In order to directly test if caffeine and A2AR inactivation indeed mitigate 
neurodegeneration, we first analyzed photomicrographs under bright field and then upon 
cresyl violet staining. Lentiviral-mediated expression of mutant ataxin-3 (LV-atx3-72Q) 
caused a clear condensation of the internal capsule attributable to striatal tissue shrinkage, 
which was evident in water-drinking mice at 12 weeks, but absent on bright-field sections of 
both caffeine-drinking animals and global A2AR knockout (KO) mice, as well as in the 
contralateral striatum challenged with wild-type ataxin-3 (LV-atx3-27Q) (Fig 2A). Cresyl violet 
staining revealed a marked reduction (p < 0.05) of the number of degenerated shrunken 
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hyperchromatic nuclei in caffeine-drinking mice even though it remained considerably high; 
the specificity of the effect over A2AR was confirmed in A2AR KO animals, which reproduced 
the alleviation of pathology observed in caffeine-treated animals (p < 0.05; Fig 2B and E). 
To further investigate the neuroprotective effects of caffeine at a late time-point in this 
model of MJD, we evaluated the immunoreactivity of the neuronal nuclear marker NeuN. A 
clear loss of NeuN-stained neurons could be seen in the water-drinking group at 12 weeks 
after mutant ataxin-3 transduction, which was not detectable after wild-type ataxin-3 
transduction, and was nearly absent in mutant ataxin-3-expressing animals upon caffeine 
treatment (Fig 2C). 
These data suggest that there is a progression in the degeneration pattern in MJD-
associated striatal pathology leading to loss of neuronal markers, which is reduced by 
chronic caffeine consumption as well as genetically deleting the A2AR. 
Neuronal functional modifications 
Previous reports have indicated that striatal neuronal dysfunction may precede 
degeneration and appearance of clinical symptoms in MJD.33 Additionally, DARPP-32 
(dopamine and cAMP-regulated phosphoprotein) was previously shown to be a sensitive 
marker that allows immunohistochemical detection of this early neuronal dysfunction.8,27,34,35 
Accordingly, DARPP-32 immunohistochemistry revealed a large depleted staining volume of 
0.60 ± 0.12 mm3 (n=5) at 4 weeks post-injection of lentivirus encoding atx3-72Q in the water-
drinking group whereas caffeine-treated animals exhibited significantly smaller dysfunctional 
volume (0.21 ± 0.06 mm3 (n=6); p < 0.05) at this time-point. No loss of DARPP-32 
immunoreactivity was detected upon LV-atx3-27Q injections (Fig 3A upper panel and B). 
At higher magnification, analysis of the striatal DARPP-32-depleted area of water-
drinking animals at 12 weeks after injection of lentiviral vectors encoding mutant ataxin-3 
revealed that the DARPP-32-stained cell bodies and the corresponding tissue (internal 
capsule) were no longer present, originating a collapse of the tissue, which joins together 
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fiber patches (see arrows in Fig 3A lower panel). This fiber accumulation presumably results 
from neuronal degeneration, which was not observed in the caffeine-treated or in A2AR KO 
mice challenged with mutant ataxin-3. Density analysis of DARPP-32 immunoreactivity 
(Table 1) showed a significant preservation of this marker in caffeine-treated (p < 0.01) and 
A2AR KO groups (p < 0.05) at 12 weeks post-injection of lentivirus encoding atx3-72Q, as 
compared to the respective water-drinking groups. 
These data suggest that both chronic caffeine consumption as well as the genetic 
deletion of A2AR is able to reduce neuronal dysfunction in MJD. 
Astrogliosis and microgliosis 
Interestingly, the mutant ataxin-3-induced loss of NeuN immunoreactivity was 
accompanied by a local increase of GFAP immunoreactivity suggestive of astrocytic 
activation, which was nearly absent in caffeine-treated animals (Fig 2D). Since reactive 
gliosis is widely accepted to contribute to chronic neurodegenerative diseases, we further 
investigated if the blockade of A2AR was able to prevent the increase of gliosis associated 
with MJD pathogenesis at an early time-point. The injection of lentiviral vectors encoding 
mutant ataxin-3 (LV-atx3-72Q) triggered a robust increase of GFAP immunoreactivity at 4 
weeks when compared with the contralateral striatum challenged with wild-type ataxin-3 (LV-
atx3-27Q) (Fig 4A). Notably, this GFAP immunoreactivity triggered by expression of mutated 
ataxin-3 was observed as early as 2 weeks (Fig 4B). Additionally, strong immunoreactivity for 
the microglial protein, cluster of differentiation molecule B11 (CD11b), was found at 4 weeks 
revealing microglial recruitment (Fig 4C), which was significantly and robustly reduced in 
caffeine-treated animals. This clearly establishes the presence of reactive gliosis in the 
striatum in this genetic model of MJD. 
Importantly, treatment with caffeine (1 g/L), prevented both the astrogliosis (Fig 4A and 
B) and the putative microgliosis (Fig 4C) triggered by mutant ataxin-3 indicating that chronic 
caffeine consumption can prevent reactive gliosis associated with MJD. 
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Nuclear inclusions of mutant ataxin-3 
Since microglia is well established to play a role in the seeding (through enhanced 
inflammatory status) and processing (through phagocytosis) of protein aggregates and the 
presence of ataxin-3 aggregates is one hallmark of MJD, we next tested the impact of 
caffeine and A2AR inactivation on the aggregation pattern of ataxin-3 by 
immunohistochemical staining. No aggregation was seen upon LV-atx3-27Q injection (Fig 
5A) while a significant increase in the total number of mutant ataxin-3 nuclear inclusions was 
observed at 8 weeks post-injection of lentiviral vectors encoding mutant ataxin-3 in both 
caffeine-drinking wild type mice (p < 0.05) as well as in A2AR KO animals (p < 0.05) when 
compared to the respective water-drinking groups (Fig 5B and C). Interestingly, we 
previously demonstrated that at 8 weeks after lentiviral transduction there were 4 times 
higher striatal levels of mutant ataxin-3 than those of endogenous ataxin-3,8 although the 
levels were similar 4 weeks after lentiviral administration. This observation that caffeine or 
A2AR inactivation enhance even more the number of ataxin-3 inclusions while decreasing 
neurodegeneration is in agreement with the scenario that these inclusions may be a way to 
sequester the soluble and noxious forms of ataxin-3. 
Synaptotoxicity 
There is accumulating evidence that one of the earliest features of neurodegenerative 
diseases is the dysfunction and loss of synapses.24,36 Also, A2AR are synaptic receptors,
37 
and A2AR blockade efficiently normalizes synaptic function and prevents synaptotoxicity in 
different animal models of brain diseases.22 Since synaptotoxicity has not been explored in 
models of MJD, we investigated whether synaptotoxicity was present in our lentiviral model 
of MJD and if this feature indeed preceded the appearance of ataxin-3 inclusions, neuronal 
dysfunction and overt neurodegeneration. This was carried out by immunohistochemical 
evaluation of two synaptic markers, synaptophysin (pre-synaptic protein) and microtubule-
associated protein 2 (MAP-2, dendritic protein). 
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Density analysis of synaptophysin and MAP-2 immunoreactivities at 2 weeks post-
injection (Table 2 and Fig 6) clearly showed a significant loss of both markers (p < 0.001) 
upon mutant ataxin-3 expression. No such early loss of either markers was observed in 
caffeine-drinking mice challenged with atx3-72Q, i.e. 2 weeks after insult or upon expression 
of wild-type ataxin-3 (data not shown). These data provide the first evidence that mutant 
ataxin-3 induces an early synaptotoxicity in the striatum, which is prevented by chronic 
caffeine consumption. 
Discussion 
In the present study, we carried out a temporal analysis of different features of brain 
dysfunction and damage in a genetic model of MJD and tested the impact of caffeine and 
adenosine A2AR (A2AR) blockade thereupon. We provide the first evidence showing that: i) 
synaptotoxicity and gliosis in the striatum are early events predating neurodegeneration; ii) 
pharmacological and genetic manipulation of adenosine A2AR can delay MJD-associated 
striatal pathology. 
Consistent with previous reports,8,13,14 lentiviral-mediated overexpression of mutant 
ataxin-3 in the mouse brain induced a clear neuronal dysfunction typified by loss of DARPP-
32 immunoreactivity, and overt neurodegeneration, accompanied by an increased number of 
ataxin-3 inclusions. The present study also revealed two novel morphological features in this 
model of MJD, namely the loss of synaptic markers (synaptotoxicity) and reactive gliosis. 
Synaptotoxicity is in line with suggestions of axonal degeneration assessed by MRI,38 and 
loss of dopaminergic terminals assessed by PET in MJD patients,11 and with the presence of 
axonal inclusions in the human patient’s brains,39 as well as with the observed impact of 
mutant ataxin-3 on the cerebellar mRNA expression of proteins involved in synaptic 
transmission.40 Notably, the present time course study provides direct evidence that this 
synaptotoxicity might be an early, hitherto unrecognised, feature of MJD. This is in notable 
agreement with the observations that another polyglutamine-related disease, namely 
Huntington’s disease is characterized by early changes in synapses,41,42 to such an extent 
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that it has been proposed that Huntington’s disease might actually be a synaptopathy.43 
Actually, it is worth noting that synaptotoxicity seems to be an early feature of different other 
neurodegenerative and neuropsychiatric diseases, strengthening the crucial role of synaptic 
impairment in the initiation of brain disorders.22,36,44 Since there is evidence that ataxin-3 is 
also located in axons and dendrites,45 the present observation that synaptic changes are an 
early feature of MJD opens a new area of research on the putative role of ataxin-3 in the 
control of synaptic function and damage. In this context, the recent report that excitatory 
synaptic transmission can control the aggregation of mutant ataxin-3 adds a further 
dimension to the relation between MJD and synaptic activity.26 
The present time course study of striatal changes in this MJD model also revealed 
another under-appreciated morphological feature that predated neuronal dysfunction and 
damage, namely reactive gliosis. There has been episodic reports of astrogliosis and 
microgliosis, typified by changes in astrocytes and microglia morphology both in patients,46 
and in transgenic models of MJD,47 as well as increased expression of cytokines and 
proinflammatory chemokines, which are compatible with mutant ataxin 3-induced changes in 
brain inflammatory mediators.48 However, in keeping with the fact that our lentiviral-mouse 
model resulted in an overexpression of mutant ataxin-3 even in comparable levels to the 
endogenous form, the present report provides evidence that reactive astrogliosis might be an 
early feature in MJD, which is particularly relevant in view of the surge of interest in the role 
of non-neuronal brain cells in the aetiology of neurodegenerative disorders.49 A putative role 
of glial cells in MJD is further heralded by evidence of the presence of ataxin-3 in glial 
cells.12,50 Again, this observation should open a novel area of research fostering a better 
understanding of the role of ataxin-3 in astrocytes and on the consequences of astrocytic 
adaptation upon accumulation of mutated ataxin-3. 
Thus, the present time-course exploration of neuropathological features associated with 
this genetic model of MJD identifies synaptotoxicity and astrogliosis as precocious 
modifications followed by microgliosis and neuronal dysfunction, appearance of NIIs and 
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overt neuronal damage. This time course is in general agreement with the recognition that 
synaptotoxicity and astrocytic-related metabolic imbalance are amongst the most precocious 
modifications in different neurodegenerative disorders and that neuroinflammation, 
previously implicated in MJD,48 may be a candidate process to mediate the spreading and 
amplification of damage until overt neuronal dysfunction and damage can be recorded.24,36,49 
The second prominent conclusion of this study is the demonstration that the chronic 
consumption of a reasonable dose of caffeine compatible to a significant blockade of 
adenosine effects on A2A (most potent) and A1 receptors 
51 or the genetic elimination of A2AR 
mitigated the striatal neuropathological modifications caused by the expression of mutated 
ataxin-3. This is in agreement with the ability of A2AR, mainly targeted by chronic caffeine 
consumption,22,52 to afford neuroprotection against different neurodegenerative disorders, 
namely Alzheimer’s, Parkinson’s or Huntington’s disease.22,25,53 Notably, most of the 
compartments that we now showed to be affected in this genetic model of MJD are 
effectively normalized by A2AR blockade in chronic brain diseases: thus, A2AR blockade 
prevents synaptotoxicity,54,55 in accordance with the enrichment of A2AR in synapses,
37 and 
also controls astrogliosis,56-58 and microgliosis,59 striatal neurodegeneration,60 and neuronal 
death.23,61 Accordingly, in our genetic model of MJD, chronic caffeine consumption or genetic 
deletion of A2AR abrogated the loss of synaptic markers, prevented astrogliosis and microglia 
activation, reduced cell injury and striatal degeneration rescuing its normal cytoarchitecture. 
Therefore, this provides the first evidence that the manipulation of a neuromodulation system 
operated by A2AR is effective in controlling the initial cascade of events triggered by the 
pathogenic ataxin-3 protein (synaptotoxicity and gliosis) that culminate in a reduced neuronal 
degeneration.  
It is worth noting that this general neuroprotection afforded by caffeine and A2AR 
blockade is accompanied by an accumulation of ataxin-3 aggregates into intracellular nuclear 
inclusions. The inverse correlation between the impact of caffeine and A2AR blockade on 
mutant ataxin-3-induced NIIs and neuropathology strongly suggests that the aggregation of 
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ataxin-3 could correspond to a cellular defensive mechanism against soluble, more toxic 
species,62-65 rather than being the main cause of degeneration. Therefore, although it cannot 
be excluded that this might result from a better neuronal survival in treated animals, we 
hypothesized that aggregates may be neuroprotective. Nevertheless, the neuroprotection 
conveyed by caffeine and A2AR blockade might be of limited duration since the number of 
pycnotic nuclei remained relatively high. 
The present exploration of the time course of MJD-associated neuropathological 
features and its modification by A2AR provides a novel insight into the neuropathology of MJD 
but does not explore the underlying mechanistic processes. Ataxin-3 is a polyubiquitin-
binding protein whose physiological function has been linked to de-ubiquitination,66-69 and 
MJD is argued to result from a toxic gain of function of mutant ataxin-3. In keeping with our 
proposal that synaptotoxicity might be a precocious modification in MJD, several studies 
highlight the importance of the ubiquitin-proteosome system (UPS) in synapses,70,71 namely 
in presynaptic terminals,72,73 where it is affected in other polyQ neurological diseases;74 
furthermore, there is preliminary evidence that A2ARs directly bind to UPS components,
75 and 
control the UPS activity,76 paving the way for a putative direct control by A2AR of synaptic 
UPS. The proposal that the ability of A2ARs to control another polyQ neurological disorder 
(Huntington’s disease) depends on the control of glutamatergic transmission prompts an 
alternative mechanism by which the A2AR-mediated control of the initial event in MJD might 
be related to the ability of A2AR to control abnormal glutamatergic transmission through direct 
synaptic effects,77 or indirectly through control of astrocytic glutamate uptake.78,79 Thus, albeit 
the molecular mechanism of A2AR-mediated control of MJD remains to be determined, the 
present study provides new clues for particular compartments where such mechanisms 
should be explored. 
In conclusion, the present study provides a novel insight into the pathology of MJD 
bringing to the centre stage synaptotoxicity and gliosis as precocious events in MJD. 
Furthermore, it provides the first realistic and safe promising life style prophylactic strategy to 
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delay the onset of this inherited disorder, based on the consumption of caffeine. Finally, it 
provides the first suggestion that A2AR might be a novel therapeutic target to interfere with 
the inexorable evolution of this neurodegenerative disease. 
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Figure Legends and Tables 
Figure 1: Summary of the time-course of appearance of different morphological features in a 
lentiviral-based model of Machado-Joseph disease. Loss of synaptic markers and 
astrogliosis were amongst the most precocious morphological alteration, closely followed by 
microgliosis and neuronal dysfunction as well as increases of the number of ataxin-3 
inclusions, whereas overt neuronal damage occurred later in the development of the disease. 
Microgliosis would probably be found at later time-points, however, that was not evaluated. 
Figure 2: Caffeine treatment or A2AR genetic depletion decreased cell injury and striatal 
degeneration. Representative bright-field photomicrographs and immunohistochemical 
stainings from around the injection site area at 12 weeks post-injection of the viral vectors 
encoding wild-type or mutant ataxin-3. (A) Coalescence of the internal capsule of the 
striatum was neither seen in the caffeine-treated group nor in the A2AR KO animals. (B) 
Cresyl violet-stained sections showed a significant reduction of the number of striatal 
condensated nuclei upon mutant ataxin-3 transduction in the caffeine-treated group as well 
as in the A2AR KO group relative to their respective water-drinking groups, as quantified in 
panel E. (C) A nearly absent loss of neuronal nuclei (NeuN) staining immunoreactivity was 
seen in the caffeine-treated group as well as in the A2AR KO group. (D) GFAP 
immunoreactivity showed an increased accumulation of astrocytes (green) replacing neurons 
after injection of mutant ataxin-3, which was prevented by caffeine consumption. No 
morphological modifications were detected upon LV-atx3-27Q injections. Statistical 
significance was evaluated with Student’s t test (*p < 0.05) comparing both caffeine-drinking 
and A2AR KO groups with their respective water-drinking wild-type groups upon LV-atx3-72Q 
injections. 
Figure 3: Caffeine treatment or A2AR genetic depletion reduced neuronal dysfunction. (A, 
upper panel) A large DARPP-32 depleted volume was observed 4 weeks after injection of 
the viral vectors encoding mutant ataxin-3 in the water-drinking group whereas caffeine-
drinking mice exhibited a much smaller lesion area at this time-point. This is quantified in 
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panel B as depleted volume of DARPP-32 staining. No loss of DARPP-32 staining was 
observed upon LV-atx3-27Q injections. (A, lower panel) At higher magnification, 12 weeks 
exposure to mutated ataxin-3 revealed a clear condensation of the internal capsule, which 
joined together fiber patches (arrows). This fiber accumulation was not observed in the 
caffeine-treated animals or in A2AR KO mice. Statistical significance was evaluated with 
Student’s t test (*p < 0.05) comparing caffeine-treated (n=6) with water-drinking animals 
(n=5). 
Figure 4: Caffeine treatment decreased MJD-associated astroglial activation and prevented 
microglia recruitment. (A) Quantification analysis of GFAP immunoreactivity at 4 weeks post-
injection of the viral vectors encoding wild-type or mutant ataxin-3. Caffeine abrogated 
astrocytic activation (##p < 0.01) to the levels induced by wild-type ataxin-3 (internal control). 
(B) Caffeine consumption attenuated the mutant ataxin-3-induced activation of astrocytes, 
gauged by enhanced immunoreactivity of Glial Fibrillary Acidic Protein (GFAP, green) at an 
earlier time point: 2 weeks. (C) No immunoreactivity for activated microglia, CD11b (Ab 5C6, 
green), was observed 4 weeks after insult in the caffeine-treated group whereas it was 
present in water-drinking mice. Statistical significance was evaluated with Student´s t test 
(**p < 0.01) comparing mutant ataxin-3 striatal hemisphere with the contralateral wild-type 
ataxin-3 hemisphere, and caffeine-drinking with water-drinking groups. 
Figure 5: Caffeine treatment or A2AR genetic depletion significantly increased the total 
number of mutant ataxin-3 inclusions. (A) Using anti-ataxin-3 antibody (Ab 1H9), no nuclear 
inclusions of ataxin-3 were found on both wild-type and A2AR KO animals upon expression of 
wild-type ataxin-3. (B) A significant increase in the number of mutant ataxin-3 inclusions was 
observed 8 weeks post-injection of lentiviral vectors encoding mutant ataxin-3 either in 
caffeine-treated (n=5) or A2AR KO (n=5) mice compared to the respective water-drinking wild-
type animals transduced with mutant ataxin-3 (B, n=7; E, n=4), as quantified in panel C. 
Statistical significance was evaluated with Student’s t test (*p < 0.05) comparing caffeine-
treated and A2AR inactivated animals with their respective water-drinking control groups. 
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Figure 6: Synaptotoxicity precedes the neurodegeneration process of MJD. Detection of 
nerve terminals with synaptic markers: synaptophysin (red) and microtubule-associated 
protein 2 – MAP-2 (Ab AP20, green). No loss of synapses is observed in the group that was 
given caffeine whereas loss of synaptophysin and MAP-2 immunoreactivity was observed in 
the non-treated group 2 weeks post-injection of the lentiviral vectors encoding mutant ataxin-
3. 
 Table 1: DARPP-32 intensity index 
Density analysis of DARPP-32 
immunoreactivity 12 weeks after mutant 
ataxin-3 transduction. Caffeine treatment as 
well as genetic inactivation of A2AR 
significantly reduced the loss of this marker (**p < 0.01; *p < 0.05, respectively). 
Note. Data are expressed as indexes of immunoreactivity of the affected striatal regions relative to 
their corresponding peripheral non-affected striatum (100% IR) [mean±SEM].  
Table 2: Synaptophysin and MAP-2 intensity indexes 
Density analysis of synaptophysin and MAP-2 2 
weeks after mutant ataxin-3 transduction. A 
significant loss of both markers was observed in 
the water-drinking control group (***p < 0.001, 
one-way ANOVA followed by Dunnett’s post-hoc 
test). No loss of either marker was observed in the caffeine-treated group. 
Note. Data are expressed as indexes of immunoreactivity of the affected striatal regions relative to 
their corresponding peripheral non-affected striatum (100% IR) [mean±SEM].  
100% IR 100.0 ± 3.5 100% IR 100.0 ± 4.1 
H2O 43.0 ± 4.1 H2O 39.1 ± 3.1 
Caffeine 70.0 ± 2.2** A2AR KO 54.5 ± 2.2* 
 Synaptophysin MAP-2 
100% IR 100.0 ± 3.5 100.0 ± 2.6 
H2O 65.5 ± 4.6*** 74.6 ± 3.0*** 
Caffeine 89.5 ± 0.6 90.1 ± 2.5 
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Figure 1: Summary of the time-course of appearance of different morphological features in a lentiviral-based 
model of Machado-Joseph disease. Loss of synaptic markers and astrogliosis were amongst the most 
precocious morphological alteration, closely followed by microgliosis and neuronal dysfunction as well as 
increases of the number of ataxin-3 inclusions, whereas overt neuronal damage occurred later in the 
development of the disease. Microgliosis would probably be found at later time-points, however, that was 
not evaluated.  
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Figure 2: Caffeine treatment or A2AR genetic depletion decreased cell injury and striatal degeneration. 
Representative bright-field photomicrographs and immunohistochemical stainings from around the injection 
site area at 12 weeks post-injection of the viral vectors encoding wild-type or mutant ataxin-3. (A) 
Coalescence of the internal capsule of the striatum was neither seen in the caffeine-treated group nor in the 
A2AR KO animals. (B) Cresyl violet-stained sections showed a significant reduction of the number of striatal 
condensated nuclei upon mutant ataxin-3 transduction in the caffeine-treated group as well as in the A2AR 
KO group relative to their respective water-drinking groups, as quantified in panel E. (C) A nearly absent 
loss of neuronal nuclei (NeuN) staining immunoreactivity was seen in the caffeine-treated group as well as in 
the A2AR KO group. (D) GFAP immunoreactivity showed an increased accumulation of astrocytes (green) 
replacing neurons after injection of mutant ataxin-3, which was prevented by caffeine consumption. No 
morphological modifications were detected upon LV-atx3-27Q injections. Statistical significance was 
evaluated with Student’s t test (*p < 0.05) comparing both caffeine-drinking and A2AR KO groups with their 
respective water-drinking wild-type groups upon LV-atx3-72Q injections.  
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Figure 3: Caffeine treatment or A2AR genetic depletion reduced neuronal dysfunction. (A, upper panel) A 
large DARPP-32 depleted volume was observed 4 weeks after injection of the viral vectors encoding mutant 
ataxin-3 in the water-drinking group whereas caffeine-drinking mice exhibited a much smaller lesion area at 
this time-point. This is quantified in panel B as depleted volume of DARPP-32 staining. No loss of DARPP-32 
staining was observed upon LV-atx3-27Q injections. (A, lower panel) At higher magnification, 12 weeks 
exposure to mutated ataxin-3 revealed a clear condensation of the internal capsule, which joined together 
fiber patches (arrows). This fiber accumulation was not observed in the caffeine-treated animals or in A2AR 
KO mice. Statistical significance was evaluated with Student’s t test (*p < 0.05) comparing caffeine-treated 
(n=6) with water-drinking animals (n=5).  
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Figure 4: Caffeine treatment decreased MJD-associated astroglial activation and prevented microglia 
recruitment. (A) Quantification analysis of GFAP immunoreactivity at 4 weeks post-injection of the viral 
vectors encoding wild-type or mutant ataxin-3. Caffeine abrogated astrocytic activation (##p < 0.01) to the 
levels induced by wild-type ataxin-3 (internal control). (B) Caffeine consumption attenuated the mutant 
ataxin-3-induced activation of astrocytes, gauged by enhanced immunoreactivity of Glial Fibrillary Acidic 
Protein (GFAP, green) at an earlier time point: 2 weeks. (C) No immunoreactivity for activated microglia, 
CD11b (Ab 5C6, green), was observed 4 weeks after insult in the caffeine-treated group whereas it was 
present in water-drinking mice. Statistical significance was evaluated with Student´s t test (**p < 0.01) 
comparing mutant ataxin-3 striatal hemisphere with the contralateral wild-type ataxin-3 hemisphere, and 
caffeine-drinking with water-drinking groups.  
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Figure 5: Caffeine treatment or A2AR genetic depletion significantly increased the total number of mutant 
ataxin-3 inclusions. (A) Using anti-ataxin-3 antibody (Ab 1H9), no nuclear inclusions of ataxin-3 were found 
on both wild-type and A2AR KO animals upon expression of wild-type ataxin-3. (B) A significant increase in 
the number of mutant ataxin-3 inclusions was observed 8 weeks post-injection of lentiviral vectors encoding 
mutant ataxin-3 either in caffeine-treated (n=5) or A2AR KO (n=5) mice compared to the respective water-
drinking wild-type animals transduced with mutant ataxin-3 (B, n=7; E, n=4), as quantified in panel C. 
Statistical significance was evaluated with Student’s t test (*p < 0.05) comparing caffeine-treated and A2AR 
inactivated animals with their respective water-drinking control groups.  
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Figure 6: Synaptotoxicity precedes the neurodegeneration process of MJD. Detection of nerve terminals with 
synaptic markers: synaptophysin (red) and microtubule-associated protein 2 – MAP-2 (Ab AP20, green). No 
loss of synapses is observed in the group that was given caffeine whereas loss of synaptophysin and MAP-2 
immunoreactivity was observed in the non-treated group 2 weeks post-injection of the lentiviral vectors 
encoding mutant ataxin-3.  
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